Next Science LLC
$829.9K 1,698 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Spineart USA Inc
Spineart USA Inc reported $830,156.56 across General Payments, Research, and Ownership to 1,361 physicians and teaching hospitals across 1,361 transactions.
- $830.2K Above-median payer
- All-tracks total
- 1,361 Top quartile volume
- Transactions
- 1,361 Top quartile reach
- Recipients
- −$2.6K
- General Payments vs PY2023
Spineart USA Inc reported $830,156.56 across all CMS Open Payments tracks (General + Research + Ownership) to 1,361 physicians and teaching hospitals in Program Year 2024 - ranking #663 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $830,156.56, averaging $609.96 per recipient.
Spineart USA Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
18/100
Transaction volume
F
20/100
Physician reach
F
20/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spineart-usa-inc Spineart USA Inc
$830.2K · #663/1,925 · 0.0% industry · PY2024
- TOT $830.2K
- RANK #663
- SHARE 0.0%
- TXN 1,361
- RCP 1,361
- CAT 3
- GEN $830.2K
- ΔGEN −$2.6K
- TOP1 4.9%
- PY 2024
Volume peers
Nearest volume peer: Next Science LLC ($829.9K)
Spineart USA Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spineart USA Inc's CMS-reported General Payments decreased by $2.6K (−0.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPINEART USA INCPY2023: SPINEART USA INCPY2024: SPINEART USA INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $832,801.87
- PY2024
- $830,156.56
What the Data Shows for Spineart USA Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Spineart USA Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $351.2K, accounting for 42.3% of this company's General Payments and 233 transactions.
General Payment Breakdown by Type
Spineart USA Inc made 3 types of general payments. "Travel and Lodging" is the largest category at $351.2K, 42.3% of General Payments.
How Spineart USA Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $351.2K | 233 | 42.3% |
| Consulting Fee | $346.4K | 143 | 41.7% |
| Food and Beverage | $132.6K | 985 | 16.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $142,596.07 (17.2%) of $830,156.56 in this company's General Payments records across 219 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spineart USA Inc
The five named recipients with the highest reported General Payments from this company
- 1
Joseph Laratta
$40,481.97 across 10 reported transactions
- 2
Warren Yu
$26,567.44 across 23 reported transactions
- 3
Torin Cunningham
$25,469.80 across 17 reported transactions
- 4
Peter Passias
$25,122.09 across 7 reported transactions
- 5
Steven Spitz
$24,954.77 across 23 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Spineart USA Inc ranks #663 of 1,925 by total payments (top 34% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,622 of 1,838 by HHI (bottom 12% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Lundbeck LLC : $4.1M total payments, HHI 159
- Foundation Fusion Solutions, LLC : $106.1K total payments, HHI 157
- Heartflow, Inc. : $1.7M total payments, HHI 157
- Globus Medical, Inc. : $27.0M total payments, HHI 156
- Saxum Surgical, Inc. : $48.5K total payments, HHI 156
- Legacy Ortho LLC : $39.6K total payments, HHI 155
- Spineart USA Inc (this company) : $830.2K total payments, HHI 154
- Medimetriks Pharmaceuticals, Inc. : $35.9K total payments, HHI 152
- Midmark Corporation : $233.6K total payments, HHI 152
- Smith+Nephew, Inc. : $46.4M total payments, HHI 151
- Dendreon Pharmaceuticals LLC : $659.8K total payments, HHI 150
- Aimmune Therapeutics, Inc. : $2.1M total payments, HHI 149
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spineart USA Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spineart USA Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spineart USA Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Spine Wave, Inc.
$825.7K 509 recipients
Compare payment profiles
Vertos Medical, Inc.
$836.6K 6,652 recipients
Compare payment profiles
Genesys Orthopedics Systems, L.L.C.
$837.2K 550 recipients
Compare payment profiles
Provepharm Inc.
$837.3K 117 recipients
Compare payment profiles
BIOTRONIK NRO, Inc.
$843.1K 9,395 recipients
Compare payment profiles
Put this to use
Spineart USA Inc ranks #663 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Spineart USA Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.